Doximity is a high-quality healthcare information business trading at a forward earnings multiple of 13 times with a PEG ratio well below 1.0, but a confirmed death-cross technical blockade, momentum below the required threshold, and falling earnings estimates create near-term headwinds that prevent the quality thesis from generating a favorable entry point today.
Thesis pillars
- Quality At Discounted Valuation→Stable
- Death Cross Technical Block→Stable
- Falling Earnings Estimates↑Improving
- +1 more pillar — see the Why tab for full reasoning
Doximity, Inc. (DOCS) Stock Analysis
Falling Knife setup · Temporary headwind edge
Healthcare · Health Information Services
Hold if already holding. Not a fresh buy at $20.42, but acceptable to hold if already in. Reasons: Thin upside margin: 8.5%; Earnings estimates trending DOWN.
Doximity operates a digital professional network for physicians with over 3 million registered members (>85% of U.S. physicians) and sells Marketing, Hiring, and Workflow Solutions to pharmaceutical manufacturers and health systems on a subscription basis. Revenue grew 13% in... Read more
Hold if already holding. Not a fresh buy at $20.42, but acceptable to hold if already in. Reasons: Thin upside margin: 8.5%; Earnings estimates trending DOWN. Chart setup: Death cross, below all MAs, RSI 28, MACD bearish. Maintain position. Not compelling to add more. Score 5.7/10, moderate confidence.
Passes 3/8 gates (clean insider activity, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and favorable risk/reward ratio and death cross (50MA < 200MA). Suitability: speculative.
About Doximity, Inc.
About Doximity, Inc.
Doximity's platform served more than 3 million registered members at March 31, 2026—representing over 85% of U.S. physicians, two-thirds of nurse practitioners and physician assistants, and approximately 90% of graduating U.S. medical students—making it the largest digital network of medical professionals in the country. Revenue grew 13% in fiscal 2026 and 20% in fiscal 2025 compared to prior-year periods, with full-time equivalent headcount reaching 880 as of March 31, 2026, up from 830 a year earlier.
Doximity earns subscription revenue from pharmaceutical manufacturers and health systems for three solution types: Marketing Solutions (sponsored digital content targeting physicians by specialty, credential, and location), Hiring Solutions (direct-message and job-post subscriptions for health system recruiters and medical staffing firms including the Curative Talent staffing division), and Workflow Solutions (telehealth via Dialer, ambient AI documentation via Scribe, clinical AI via Ask, and on-call scheduling via AMiON). More than 140 leading U.S. health systems have adopted the Clinical AI Suite. Pharmaceutical manufacturers purchase programs on a brand-by-brand basis. One customer represented 10% or more of total revenue in fiscal 2026; the company typically does not enter long-term contracts with pharmaceutical manufacturer customers, who represent a significant portion of revenue. Named competitors include LinkedIn, WebMD's Medscape, OpenEvidence, Zoom Video Communications, Teladoc Health, Abridge, OpenAI, and Anthropic across overlapping product categories.
Show full overview
Customer concentration is the most concretely quantified risk: one unnamed customer crossed the 10% of total revenue threshold for fiscal year ended March 31, 2026—the first time this occurred, as no customer met the 10% threshold in fiscal 2025 or 2024. Pharmaceutical manufacturer customers, who represent a significant portion of revenue, are not typically bound by long-term contracts and may redirect marketing spend to competitors or reduce digital budgets in response to macroeconomic pressures, tariffs, or regulatory delays affecting their own businesses. In April 2026, Doximity disclosed via Form 8-K the CFO's resignation and appointment of an interim principal financial officer.
See also: Healthcare · Health Information Services
From Doximity, Inc.'s most recent 10-K filing, extracted June 9, 2026.
Recent developments
updated 2026-07-26Recent Developments — Doximity, Inc.
Latest news
- NEWS Doximity Stock Dives On Q4 Earnings, Weak Outlook - Benzinga — Benzinga negative
- NEWS Doximity (NYSE:DOCS) Posts Q1 CY2026 Sales In Line With Estimates But Stock Drops 11.1% - Yahoo Finance — Yahoo Finance negative
- NEWS Doximity (DOCS): Buy, Sell, or Hold Post Q4 Earnings? - StockStory — StockStory neutral
- NEWS Doximity (DOCS) Q1 Earnings: What To Expect - StockStory — StockStory neutral
- NEWS Doximity (DOCS) Q1 Earnings: What To Expect - TradingView — TradingView neutral
Generated 2026-07-26T08:02:04Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- LOWCustomerone customer 10% or more of total revenue10-K Item 1A: 'one customer accounted for 10% or more of total revenue for the fiscal year ended March 31, 2026'
- MEDIUMCustomerpharmaceutical manufacturer customers10-K Item 1A: 'pharmaceutical manufacturer customers, who represent a significant portion of our revenue'
Material Events(8-K, last 90d)
- 2026-04-17Item 5.02MEDIUMCFO Anna Bryson resigned effective April 13, 2026, having been on medical leave since February 2026. Chief Accounting Officer Siddharth Sitaram appointed interim principal financial officer effective Feb 3, 2026; permanent CFO search ongoing at time of filing.SEC filing →
- 2026-05-13Item 5.02LOWMatthew Sonefeldt appointed Chief Financial Officer effective May 2026, succeeding interim CFO Siddharth Sitaram. No reason for succession cited beyond resolution of prior CFO departure.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Growth below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $20.42, but acceptable to hold if already in. Reasons: Thin upside margin: 8.5%; Earnings estimates trending DOWN. Chart setup: Death cross, below all MAs, RSI 28, MACD bearish. Maintain position. Not compelling to add more. Target $22.15 (+8.5%), stop $19.25 (−6.1%), A.R:R 0.9:1. Score 5.7/10, moderate confidence.
Take-profit target: $22.15 (+8.5% upside). Target $22.15 (+8.5%), stop $19.25 (−6.1%), A.R:R 0.9:1. Stop-loss: $19.25.
Thin upside margin: 8.5%; Earnings estimates trending DOWN; Weak growth.
Doximity, Inc. trades at a P/E of 20.8 (forward 12.8). TrendMatrix value score: 7.1/10. Verdict: Hold.
29 analysts cover DOCS with a consensus score of 3.6/5. Average price target: $25.
What does Doximity, Inc. do?Doximity operates a digital professional network for physicians with over 3 million registered members (>85% of U.S....
Doximity operates a digital professional network for physicians with over 3 million registered members (>85% of U.S. physicians) and sells Marketing, Hiring, and Workflow Solutions to pharmaceutical manufacturers and health systems on a subscription basis. Revenue grew 13% in fiscal 2026 and 20% in fiscal 2025 versus prior years.